期刊文献+

Effects of angiotensin Ⅱ receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats 被引量:5

Effects of angiotensin Ⅱ receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats
原文传递
导出
摘要 Background Diabetic nephropathy is a major cause of renal failure in diabetes mellitus (DM). It has been known that renin-angiotensin system (RAS) blockers have a renal protective effect. This study aimed to investigate whether treatment with angiotensin Ⅱ receptor blocker, olmesartan, could modify renal hemodynamic variables and vascular structural properties, then attenuate renal injury in streptozotocin (STZ)-induced DM rats.Methods DM was induced in male Wistar rats by intraperitoneal administration of STZ. The rats were then randomized to a DM group and an olmesartan treatment (OLM+DM) group. The normal group (non-DM) were administered only citrate buffer. At the end of the 14th week, blood glucose, kidney weight/body weight and urinary protein-to-creatinine ratio were determined. Further, the flow-pressure and pressure-glomerular filtration rate (GFR) relationships were determined for maximally vasodilated, perfused kidneys. From the relationship, 3 indices of vascular structural properties were estimated: slope of flow-pressure (minimal renal vascular resistance, reflecting overall luminal dimensions of preglomerular and postglomerular vasculature), slope of pressure-GFR (glomerular filtration capacity against pressure)and threshold pressure for beginning filtration at pressure-GFR (preglomerular to postglomerular vascular resistance ratio). Kidneys were then perfusion fixed for histological analysis. The renal histopathology was observed by light microscopy.Results The body weight of DM rats was lower than that of non-DM rats. Blood glucose, kidney weight/body weight,urinary protein-to-creatinine ratio were significantly greater in DM rats than in non-DM rats. The parameters such as kidney weight/body weight, urinary protein-to-creatinine ratio in OLM+DM rats had dramatically decreased compared with those in DM rats. However, the treatment with olmesartan had no effect on blood glucose levels. The slope of flow-pressure relationship was greater in DM rats than that in non-DM rats (P 〈0.05). But the slope of the pressure-GFR relationship was lower in DM rats than that in non-DM rats (P 〈0.05) with the x-intercept of the line similar between the two groups. The slope of the flow-pressure relationship was decreased in DM rats group treated with olmesartan (P 〈0.05). Moreover, olmesartan significantly increased the slope of the pressure-GFR relationship in DM rats (P 〈0.05).The x-intercept of the pressure-GFR relationship reduced following olmesartan in DM rats.Conclusions Treatment with olmesartan reduced urinary protein-to-creatinine ratio independent of blood glucose and increased average renal vessel lumen diameter in the perfused kidneys of STZ-induced DM rats, predominantly in preglomerular vessels, and then improved renal excretory capability. These findings were consistent with remodeling of the preglomerular vasculature in our hisological measurements. Background Diabetic nephropathy is a major cause of renal failure in diabetes mellitus (DM). It has been known that renin-angiotensin system (RAS) blockers have a renal protective effect. This study aimed to investigate whether treatment with angiotensin Ⅱ receptor blocker, olmesartan, could modify renal hemodynamic variables and vascular structural properties, then attenuate renal injury in streptozotocin (STZ)-induced DM rats.Methods DM was induced in male Wistar rats by intraperitoneal administration of STZ. The rats were then randomized to a DM group and an olmesartan treatment (OLM+DM) group. The normal group (non-DM) were administered only citrate buffer. At the end of the 14th week, blood glucose, kidney weight/body weight and urinary protein-to-creatinine ratio were determined. Further, the flow-pressure and pressure-glomerular filtration rate (GFR) relationships were determined for maximally vasodilated, perfused kidneys. From the relationship, 3 indices of vascular structural properties were estimated: slope of flow-pressure (minimal renal vascular resistance, reflecting overall luminal dimensions of preglomerular and postglomerular vasculature), slope of pressure-GFR (glomerular filtration capacity against pressure)and threshold pressure for beginning filtration at pressure-GFR (preglomerular to postglomerular vascular resistance ratio). Kidneys were then perfusion fixed for histological analysis. The renal histopathology was observed by light microscopy.Results The body weight of DM rats was lower than that of non-DM rats. Blood glucose, kidney weight/body weight,urinary protein-to-creatinine ratio were significantly greater in DM rats than in non-DM rats. The parameters such as kidney weight/body weight, urinary protein-to-creatinine ratio in OLM+DM rats had dramatically decreased compared with those in DM rats. However, the treatment with olmesartan had no effect on blood glucose levels. The slope of flow-pressure relationship was greater in DM rats than that in non-DM rats (P 〈0.05). But the slope of the pressure-GFR relationship was lower in DM rats than that in non-DM rats (P 〈0.05) with the x-intercept of the line similar between the two groups. The slope of the flow-pressure relationship was decreased in DM rats group treated with olmesartan (P 〈0.05). Moreover, olmesartan significantly increased the slope of the pressure-GFR relationship in DM rats (P 〈0.05).The x-intercept of the pressure-GFR relationship reduced following olmesartan in DM rats.Conclusions Treatment with olmesartan reduced urinary protein-to-creatinine ratio independent of blood glucose and increased average renal vessel lumen diameter in the perfused kidneys of STZ-induced DM rats, predominantly in preglomerular vessels, and then improved renal excretory capability. These findings were consistent with remodeling of the preglomerular vasculature in our hisological measurements.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第4期562-567,共6页 中华医学杂志(英文版)
关键词 diabetic nephropathy angiotensin receptor antagonist renal vascular structure vasodilated perfused kidney diabetic nephropathy angiotensin Ⅱ receptor antagonist renal vascular structure vasodilated perfused kidney
  • 相关文献

参考文献25

  • 1Hidai H.Need for an incentive-based reimbursement policy toward quality care for dialysis patient management.Kidney Int 2000; 58:363-373.
  • 2Ritz E,Rychlik I,Locatelli F,Halimi S.End-stage renal failure in type 2 diabetes:A medical catastrophe of worldwide dimensions.Am J Kidney Dis 1999; 34:795-808.
  • 3American Diabetes Association.Standards of medical care in diabetes (Position Statement).Diabet Care 2005; 28:S4-S36.
  • 4Mizuno M,Sada T,Kato M,Fukushima Y,Terashima H,Koike H.The effect of angiotensin Ⅱ receptor blockade on an end-stage renal failure model of type 2 diabetes.J Cardiovasc Pharmacol 2006; 48:135-142.
  • 5Rincon-Choles H,Kasinath BS,Gorin Y,Abboud HE.Angiotensin Ⅱ and growth factors in the pathogenesis of diabetic nephropathy.Kidney Int 2002; 82 (Supp 1):S8-S11.
  • 6Berl T.Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection:The case for AT1 receptor antagonist.J Am Soc Nephrol 2004;15(Supp 1):S71-S76.
  • 7Deferrari G,Ravera M,Deferrari L,Vettoretti S,Ratto E,Parodi D.Renal and cardiovascular protection in type 2 diabetes mellitus:Angiotensin Ⅱ receptor blockers.J Am Soc Nephrol 2002; 13(Supp 13):S224-S229.
  • 8Carey RM,Siragy HM.The intrarenal renin-angiotensin system and diabetic nephropathy.Trends Endocrinol Metab 2003; 14:274-281.
  • 9Viberti G,Wheeldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:A blood pressure-independent effect.Circulation 2002; 106:672-678.
  • 10Brenner BM,Cooper ME,de Zeeuw D,Keane WF,Mitch WE,Parving HH,et al.RENAAL Study Investigators:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med 2001; 345:861-869.

同被引文献36

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部